Results 141 to 150 of about 11,489 (193)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans. [PDF]

Vaccines (Basel)
Tscherne A, Kalodimou G, Kupke A, Rohde C, Freudenstein A, Jany S, Kumar S, Sutter G, Krähling V, Becker S, Volz A.   +10 more
europepmc   +1 more source

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. [PDF]

Lancet Infect Dis, 2020
Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM.   +24 more
europepmc   +1 more source

Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice [PDF]

, 2010
Christine Meisinger-Henschel, Michaela Späth, Susanne Lukassen, Michael Wolferstätter, Heike Kachelriess, Karen Baur, Ulrike Dirmeier, Markus Wagner, Paul Chaplin, Mark Suter, Jürgen Hausmann   +10 more
openalex   +1 more source

Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice. [PDF]

J Virol
Zhu J, Wang Z, Li Y, Zhang Z, Ren S, Wang J, Xie S, Liao Z, Song B, Wu W, Yan F, Peng C.   +11 more
europepmc   +1 more source

Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

, 2007
D. Huw Davies, Linda S. Wyatt, Frances K. Newman, Patricia L. Earl, Sookhee Chun, Jenny E. Hernandez, Douglas M. Molina, Siddiqua Hirst, Bernard Moss, Sharon E. Frey, Philip L. Felgner   +10 more
openalex   +1 more source

Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages. [PDF]

Front Immunol
Neckermann P, Mohr M, Billmeier M, Karlas A, Boilesen DR, Thirion C, Holst PJ, Jordan I, Sandig V, Asbach B, Wagner R.   +10 more
europepmc   +1 more source

Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly ⁺ Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis [PDF]

, 2011
Elma Tchilian, Christiane Desel, Emily Forbes, Silke Bandermann, Clare R. Sander, Adrian V. S. Hill, Helen McShane, Stefan H. E. Kaufmann   +7 more
openalex   +1 more source

Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus. [PDF]

Front Immunol
Diaz-Cánova D, Moens U, Brinkmann A, Nitsche A, Okeke MI.   +4 more
europepmc   +1 more source

Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax® using proteome microarrays and development of recombinant protein ELISAs [PDF]

, 2011
Gary Hermanson, Sookhee Chun, Jiin Felgner, Xiaolin Tan, Jozelyn Pablo, Rie Nakajima‐Sasaki, Douglas M. Molina, Philip L. Felgner, Xiaowu Liang, D. Huw Davies   +9 more
openalex   +1 more source

Immunity to Tick-Borne Encephalitis Virus NS3 Protein Induced with a Recombinant Modified Vaccinia Virus Ankara Fails to Afford Mice Protection against TBEV Infection. [PDF]

Vaccines (Basel)
Kubinski M, Beicht J, Gerlach T, Aregay A, Osterhaus ADME, Tscherne A, Sutter G, Prajeeth CK, Rimmelzwaan GF.   +8 more
europepmc   +1 more source